Dr. Heidi Overton appeared before the Senate HELP Committee on Thursday to address how she would run the Food and Drug Administration if confirmed as its next commissioner.

For two hours, senators tested the 37-year-old physician and current Deputy Assistant to the President for Domestic Policy on topics ranging from maintaining food safety to lowering prescription prices. For specialty dispensing pharmacies, however, the consequential questions were narrower: would the agency accelerate access to rare-disease treatments? Would it change the rules for dispensing abortion drugs? And when politicians and FDA scientists disagree, how would Overton respond?

Here are the main takeaways for pharmacies that manage complex therapies and the patients waiting for them.

Expect faster drug development and approvals

Overton called speeding up treatments for rare conditions when large trials are impractical “a priority.”

She pointed to the agency’s plausible-mechanism approach and suggested formalizing more flexible, risk-based reviews for very small patient groups.

“We should think about N of 5, N of 20 … where having the flexibility and the risk-based review determinations [makes sense.] Where people are willing to take more risk,” Overton said. “I would want to use all of the statutory authority we can, if I’m confirmed, to expedite that.”

She also addressed the “review lottery” problem, in which drugs can be held to different standards based on their assigned reviewer.

“It’s very important that there [are] best practices across reviewers … frontier science doesn’t matter if it’s not accessible to patients,” Overton said.

Overton said Trump had directed her to “go fast” to speed drug approvals. She pledged to continue work on clinical-trial and drug-development reform, describing competition with China as a forcing function to bring development back to the United States.

For specialty pharmacies, Overton’s support for more flexible rare-disease approvals could be welcome news: more patients may have a treatment option where none existed before. But she offered few details about how that approach would work in practice.

How would the FDA apply the same standards across reviewers? Which therapies would qualify? And, importantly, how quickly could pharmacies prepare to dispense them? Faster rare-disease approvals could mean more therapies to onboard, sometimes for patient populations so small that each case requires substantial coordination. And patients may still face limited distribution, coverage denials, prior authorization requirements and delays before they receive a first dose.

FDA can rewrite dispensing rules for drugs already on the market

Senators from both parties pressed Overton on the FDA’s ongoing safety review of mifepristone, an abortion medication subject to a Risk Evaluation and Mitigation Strategy, or REMS. REMS determine which pharmacies may dispense a drug, which patients must be enrolled, and what must be verified before a prescription ships.

The hearing serves as a reminder to the pharmacy industry that such requirements can change, even after a drug is on the market.

Overton said mifepristone is "safe and effective as labeled today" under its current REMS, but declined to predict whether the agency's ongoing safety review will change the label.

Sen. Patty Murray, D-Wash., and Sen. Maggie Hassan, D-N.H., called for Overton to recuse herself from any mifepristone-related safety studies and ensure career scientists lead them, noting she had published an article in 2023 that labeled the drug “dangerous.”

Sen. Josh Hawley, R-Mo., on the other hand, criticized Overton for being seemingly too positive about the drug.

“I’m confused by [your stance], though, because that’s not the FDA’s position in court,” he said, referring to litigation over the drug’s dispensing rules. Hawley said he was looking forward to the FDA finishing its safety study, calling the document “long overdue.”

A change to the REMS could affect pharmacy certification, patient access or the steps required before a prescription can be dispensed. Sen. Lisa Murkowski, R-Alaska, pointed to this in her questioning, worrying that enhanced telehealth restrictions on the drug would be devastating for care access in her home state.

Overton hedges on boundary between White House priorities and FDA

Ahead of Thursday’s hearing, senators from both sides of the aisle expressed concern about Overton’s ability to stand up to the president should he make unevidenced medical claims. Her presence at an August executive order signing, where the president said U.S. children received too many vaccines and the combined MMR vaccine should be administered as three separate shots, drew particular alarm.

Committee Chair Dr. Bill Cassidy, R-La., asked Overton to commit to making decisions based on science instead of ideology. He added that he’d received such promises from nominees before, including Health Secretary Robert F. Kennedy Jr., only to have them renege on their commitments once confirmed.

“That’s his ethics system. I need to know your ethics system,” said Cassidy, saying her confirmation was conditioned on demonstrating commitment to “radical honesty.”

Overton said the president can set policy priorities, while individual product decisions belong with the FDA’s career staff at the relevant center and must follow statutory safety and efficacy standards.

However, she repeatedly refused to say she would correct misinformation from the White House. Sen. Blunt Rochester, D-Del., for example, asked her to disavow Trump’s statement that children receive vaccines “the size of a soda bottle.” Overton did not directly say he was wrong.

“I’m really concerned about the science piece, the implementation [of three new solo vaccines], and ultimately the fact that we're in the middle of the largest measles outbreak in three decades,” said Blunt Rochester. “We hope that you will use science if you're confirmed, and we hope that you will stand up if the information is incorrect or wrong because people's lives are on the line.”

For pharmacists, the FDA’s independence is critically important. Their businesses rely on clear, durable FDA determinations when they build processes around a product’s indication, label and safety program. The hearing showed how difficult that boundary may be to maintain. Overton went as far as stating the MMR vaccine is safe — contradicting Trump’s comments that the vaccine can be “lethal” — but she would not directly speak negatively of her boss.

When Hassan asked her if the president could ever be wrong, Overton responded: “It is the president who sets the policy directions, but he works with all of his advisors to get the best information. My experience has been he wants to make the best decision.”